CONSTELLATION TECHNOLOGIES LIMITED — Regulatory Filings 2011

Jun 26, 2011

==> picture [99 x 86] intentionally omitted <==

ASX Announcement

Clinical benefits of lead diagnostic to be showcased at international medical conference in China

Melbourne, Australia, 27 June 2011; China-focused drug and diagnostic company Agenix (ASX: AGX) today confirmed its proprietary diagnostic for the detection of pulmonary embolism, ThromboView[®] , will be featured at the 4th Annual International Conference of Molecular Diagnostics in Beijing China in September 2011.

Agenix will be the only Australian company to present at the international conference which will showcase the latest advances in molecular diagnostics.

Venous thromboembolism (VTE) is a disease that includes deep vein thrombosis (DVT) and pulmonary embolism (PE). It is the third most common cardiovascular illness after acute coronary syndrome and stroke. It is the third most common cause of hospital-related death and the most common preventable hospital-related death due to a failure by available medical technology to accurately diagnose this life threatening problem. In the USA alone, there are 600,000 clinically recognized incidences of thromboembolism annually.

ThromboView was developed to address this significant unmet medical need and provide medical professionals worldwide with a more accurate test that can be used anywhere in the body without exposing patients to toxic contrast agents and the high radiation of a CT scan.

Agenix’s Director of Research and Product Development for ThromboView, Dr Mike Gerometta, will present clinical efficacy and safety data and highlight the potential of ThromboView® as a new standard treatment in hospitals worldwide. He will also chair an expert panel focused on the latest developments in the detection of hemostasis and thrombosis.

A copy of the presentation will be made available on the Agenix website on the same day.

Agenix Chief Executive Officer Nicholas Weston said, "There is growing international interest among the medical community for a more accurate way to diagnose life threatening blood clots. This interest is driven by a growing body of clinical evidence that demonstrates ThromboView[®] affords a number of potential benefits to patients who currently have limited options available.”

Thromboview® has successfully completed two US Food and Drug Administration (FDA) Phase II human clinical trials. Agenix has revitalized its partnering program for this valuable late stage technology and is currently working to establish a number of solid, financially beneficial opportunities with global medical and pharmaceutical partner organisations to help expedite the final clinical phase for the US and European regulatory approval of ThromboView®.

Agenix aims to create access to technology and royalty revenue streams which will extend beyond expiry of its patents in 2022, namely 12 years from the date of regulatory approval for biologics in the USA and 10 years in Europe.

The current standard for diagnosing pulmonary embolism is a procedure called computed tomography pulmonary angiography (CTPA). It delivers a substantial radiation dose and involves the injection of a contrast agent, through the patient’s leg or arm. A CAT scanner then takes a series of images of the lungs from different angles.

ThromboView offers a more accurate test without exposing patients to pulmonary angiography contrast agents which can be highly toxic to the kidneys, nor to the high radiation dosages associated with CT.

Thromboview only requires only a standard hospital gamma camera to take a single photon emission tomography (SPECT) image from which the reader can easily identify the presence, absence and location of a blood clot.

For further information please contact:

Nicholas Weston Andrew Geddes Agenix Limited CoActive Health Communications Tel: 1300 132 551 Tel: (02) 9555 4453

® ThromboView is a registered trademark of Agen Biomedical Limited, a wholly owned subsidiary of Agenix Limited.